Soligenixincis A Late Stage Biopharmaceutical Company Based In Princetonnew Jerseyfounded In 1987The Company Focuses On Developing Therapies For Rare Diseases And Unmet Medical Needssoligenix Operates Through Two Main Segmentsspecialized Biotherapeutics And Public Health Solutionsthe Company Is Publicly Traded On Nasdaq Under The Ticker Sngx And Has A Market Capitalization Of $22 1 Million In The Specialized Biotherapeutics Segmentsoligenix Is Advancing Several Treatmentsincluding Hybrytea C For Cutaneous T Cell Lymphoma And Sgx942 For Oral Mucositis In Head And Neck Cancer Patientsthe Public Health Solutions Segment Develops Vaccines And Biodefense Countermeasuressuch As The Rivaxaricin Toxin Vaccine And A Covid 19 Vaccine Candidatewith A Dedicated Team Of Approximately 15Ae 20 Employeessoligenix Is Committed To Addressing Critical Healthcare Challenges Through Its Innovative Therapies And Solutions
